Our mission is simple—help patients across the globe who suffer from pain and chronic conditions. We are doing this by harnessing the power of nVNS, innovation, and technology to develop a safe and clinically backed treatment. Bringing new treatments to market will help improve patients' treatment options and lives.
Generated first quarter revenue of $734,000 Secured FDA clearance of gammaCore ™ (nVNS) label expansion for migraine prevention Announced initiatives to support the potential use of nVNS for the treatment of symptoms associated with COVID-19 Company to host conference call and webcast today, May
Conference Call to be Held at 4:30pm Eastern Time BASKING RIDGE, N.J. , May 07, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the first quarter ended March 31, 2020 after the close of
Randomized controlled investigator-initiated trial (IIT) of non-invasive vagus nerve stimulation (nVNS) therapy currently enrolling COVID-19 patients in Spain Peer-reviewed paper, “Use of Non-Invasive Vagus Nerve Stimulation to Treat Respiratory Symptoms Associated with COVID-19: A Theoretical